Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Margarida Simão Rafael"'
Autor:
Margarida Simão-Rafael, Ofelia Cruz, Sara Perez-Jaume, Vicente Santa-María Lopez, Cinzia Lavarino, Hector Salvador, Jordi Muchart López, Jose Hinojosa, Mariona Suñol, Andrés Morales La Madrid
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100115- (2023)
Purpose: Pediatric low-grade gliomas (PLGG) have an excellent overall survival, but frequently need non-surgical therapy at diagnosis or after progression when located in unresectable sites such as the optic pathway. Chemotherapy side effects have le
Externí odkaz:
https://doaj.org/article/f2d57bd5b71144dd9db7415e54187a25
Autor:
Benjamin J. Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D. Weiss, Michelle Choe, Jennifer H. Foster, Navin Pinto, Daniel A. Morgenstern, Margarida Simão Rafael, Keri A. Streby, Rachel N. Zeno, Rajen Mody, Sahr Yazdani, Ami V. Desai, Margaret E. Macy, Suzanne Shusterman, Sara M. Federico, Rochelle Bagatell
Publikováno v:
Journal of Clinical Oncology. 41:508-516
PURPOSE Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macroph
Autor:
Karsten Nysom, Andrea Gomez Morad, Margarida Simão Rafael, Judith Zier, Araz Marachelian, Tanya Watt, Daniel A. Morgenstern
Publikováno v:
Pediatric Blood & Cancer. 70
Autor:
Daniel Morgenstern, Karsten Nysom, Andrea Gomez Morad, Margarida Simão Rafael, Judith Zier, Araz Marachelian, Tanya Watt
Monoclonal antibodies (mAbs) targeting disialoganglioside 2 (GD2) are an important treatment advance for high-risk neuroblastoma, including in patients with refractory or relapsed disease. Dinutuximab and dinutuximab beta are administered for ≥8 ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b8c65f737418c818aa603c6d53464c9
https://doi.org/10.22541/au.166625465.50540612/v1
https://doi.org/10.22541/au.166625465.50540612/v1
Autor:
Margarida Simão Rafael, Ofelia Cruz, Sara Perez-Jaume, Vicente Santa-María, Cinzia Lavarino, Hector Salvador, Jordi Muchart, Jose Hinojosa, Mariona Suñol, Andrés Morales
Publikováno v:
Neuro-Oncology. 24:i95-i95
PURPOSE: Pediatric low-grade gliomas (PLGG) have excellent overall survival but frequently need non-surgical therapy at diagnosis or after progression at unresectable sites such as the optic pathway. Chemotherapy side effects have led to the need for